Drug intelligence / Profile preview

MOG2

Development stage: Preclinical
Lead developer: Mogrify
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Local Injection

Overview

MOG2 is an experimental therapeutic candidate being developed by Mogrify for the treatment of sensorineural hearing loss. It utilizes the company's proprietary MOGRIFY platform to perform in vivo direct cellular reprogramming. The approach involves the delivery of specific transcription factors via a viral vector to convert existing mature cells within the inner ear into functional cell types, such as hair cells, to restore lost auditory function. By bypassing the need for stem cell intermediates or ex vivo cell manipulation, MOG2 aims to regenerate degenerate cell populations directly within the patient's tissue.

Targets

TF (Transferrin)

Beyond the preview

Go deeper on MOG2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MOG2.

Explore the full profile